<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825824</url>
  </required_header>
  <id_info>
    <org_study_id>K-1205-001-005</org_study_id>
    <secondary_id>KCT0000454</secondary_id>
    <secondary_id>KROG 12-02</secondary_id>
    <secondary_id>K-1205-001-005</secondary_id>
    <nct_id>NCT01825824</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm</brief_title>
  <official_title>Multicenter Phase II Study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dongnam Institute of Radiological &amp; Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea Cancer Center Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment for hepatocellular carcinoma (HCC) is surgery, such as, by hepatic
      resection or liver transplantation, but less than 20% of HCC patients are suitable for
      surgery. In the remaining patients with inoperable and advanced HCC, trans-arterial
      chemo-embolization (TACE) has been widely used but TACE alone rarely produces complete
      response and commonly develops recurrence. Recently several small studies reported high tumor
      response and local control rate after stereotactic ablative radiotherapy (SABR) alone or with
      TACE for inoperable HCC. This study will evaluate SABR effect with 60 Gy in 3 fractionations
      for HCC with size of ≤ 5 cm and 3 cm apart from gastrointestinal tract.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>From the date of SABR to the date of local failure or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>From the date of SABR to the date of death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>From the date of SABR to the date of first failure or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic recurrence free survival rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>From the date of SABR to the date of Intrahepatic recurrence or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Adverse events using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; Classic radiation induced liver disease; Non-classic Classic radiation induced liver disease; Worsening of Child-Turcotte-Pugh score; Worsening of MELD score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Stereotactic ablative radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic ablative radiotherapy</intervention_name>
    <description>The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by &gt;48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of &gt; 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of &gt; 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.</description>
    <arm_group_label>Stereotactic ablative radiotherapy</arm_group_label>
    <other_name>Stereotactic body radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥ 20 years of age

          -  Initially diagnosed or recurrent hepatocellular carcinoma (HCC)

          -  Unresectable HCC

          -  Cirrhotic status of Child Pugh class A or B7

          -  Eastern Cooperative Oncology Group performance status 0 or 1

          -  single or sum of multiple tumor ≤ 5 cm

          -  HCC with 3 cm apart from gastrointestinal tract

          -  The volume of uninvolved must be at least 700 ml

          -  Incomplete response after trans-arterial chemo-embolization of 1-5

          -  A single lesion or multiple lesions including portal vein tumor thrombosis included in
             radiation field with one or consecutive sessions of stereotactic body radiation
             therapy (SBRT)

          -  No evidence of an uncontrolled lesion at any other site

          -  No evidence of complications of liver cirrhosis

          -  No evidence of uncontrolled inter-current illness

          -  Patient or guardian must be able to provide verbal and written informed consent

        Exclusion Criteria:

          -  Patient with previous history of abdominal radiation

          -  Direct invasion to esophagus, stomach or colon by HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mi-Sook Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>612-896</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongnam Institute of Radiological &amp; Medical Sciences</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea Cancer Center Hospital</investigator_affiliation>
    <investigator_full_name>Mi-Sook Kim</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Stereotactic ablative radiotherapy</keyword>
  <keyword>Stereotactic body radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

